BlackRock Files Extensive Form 604 Detailing Changes in Cochlear Limited Shareholding

Implications of the Form 604 Filing for Cochlear Investors

Under the Corporations Act 2001, a Form 604 must be filed by substantial shareholders—those owning 5% or more of a company's voting shares—whenever their relevant interest changes. BlackRock's filing relating to Cochlear Limited indicates that transactions across its group entities altered its aggregate relevant interest in COH, triggering this disclosure requirement.

For shareholders and market watchers, such filings from major institutional investors are common among ASX-listed large-cap companies. The extensive 430-page document reflects the scale and complexity of BlackRock's investment operations rather than any single major portfolio move. Nevertheless, it offers a detailed account of how one of the world’s largest asset managers positioned itself in COH shares during the last week of April 2021.

Diverse BlackRock Entities Involved in Hundreds of COH Transactions

The filing names numerous BlackRock subsidiaries involved in the disclosed transactions, including BlackRock Fund Advisors, BlackRock Advisors (UK) Limited, BlackRock Investment Management (Australia) Limited, BlackRock Institutional Trust Company National Association, BlackRock Investment Management LLC, BlackRock Investment Management (UK) Limited, BlackRock Financial Management Inc., BlackRock Japan Co. Ltd., BlackRock (Singapore) Limited, BlackRock Asset Management North Asia Limited, BlackRock Asset Management Canada Limited, BlackRock Advisors LLC, and APERIO GROUP LLC.

This wide array of entities aligns with BlackRock’s global operational model, where different subsidiaries manage distinct investment mandates—such as index funds, active strategies, and securities lending programs—that can lead to simultaneous buying and selling of the same security. The presence of concurrent buying and selling activity across BlackRock entities on identical dates in COH shares is typical and reflects internal portfolio management rather than conflicting market views.

On-Market COH Trades Executed Between AUD $222.23 and AUD $224.72

The update details on-market transactions in COH ordinary shares conducted on 26, 27, 28, and 29 April 2021. On 26 April, BlackRock Investment Management (Australia) Limited sold shares on-market at AUD $223.96 each, while BlackRock Advisors (UK) Limited purchased shares at AUD $223.77, and BlackRock Institutional Trust Company National Association also sold at AUD $223.77.

Similar patterns occurred on subsequent days. On 27 April, BlackRock Investment Management (Australia) Limited bought shares at AUD $222.23, while BlackRock Institutional Trust Company National Association executed several sell transactions at the same price. On 28 April, BlackRock Investment Management (UK) Limited acquired 7,185 COH shares at AUD $224.17, marking one of the larger single on-market trades disclosed. On 29 April, sell transactions were recorded at AUD $224.42, with a purchase by BlackRock Advisors (UK) Limited at AUD $224.72. Overall, the price range during this period was approximately AUD $222.23 to AUD $224.72 per ordinary share.

Significant In Specie Transfers Among BlackRock’s COH Activities

In addition to standard on-market trades, a large portion of the transactions are classified as "in specie" transfers, which involve no cash consideration (noted as "n/a" in the filing). These transfers typically relate to the creation or redemption of units in exchange-traded funds or other pooled investment vehicles managed by BlackRock, where COH shares are exchanged for fund units rather than cash.

BlackRock Fund Advisors, a key ETF manager within BlackRock, is the most frequently cited entity for in specie transactions during the disclosed dates. On 26 April alone, it recorded six separate in specie transfers ranging from additions of 280 shares to reductions of 72 shares. Similar small-lot in specie transactions continued on 27, 28, and 29 April. APERIO GROUP LLC, which manages customized index separate accounts, also recorded in specie transactions denominated in USD referencing American Depositary Receipts with a 1:2 ADR-to-ordinary share ratio.

Collateral Transfers Highlight COH Shares Used in Lending and Financing

The filing also includes collateral transfers, which involve no cash and represent COH shares used as collateral within BlackRock’s securities lending and financing operations. These transactions can involve substantial volumes of shares moving between BlackRock entities or with external counterparties as part of short-term lending arrangements.

Notable examples include a collateral transfer of 46,694 COH shares into BlackRock Japan Co. Ltd. on 26 April, alongside negative collateral transfers of 27,891 and 27,354 shares by BlackRock Investment Management LLC and BlackRock Investment Management (UK) Limited, respectively. On 27 April, BlackRock Investment Management (UK) Limited recorded a positive collateral transfer of 53,975 shares. Such large movements are typical in institutional securities lending programs and do not necessarily indicate changes in beneficial ownership.

APERIO GROUP LLC’s ADR Transactions Introduce US Market Exposure

APERIO GROUP LLC’s inclusion adds a US market dimension to the filing. Operating within BlackRock, APERIO recorded in specie ADR transactions over multiple dates with a 1:2 conversion ratio, meaning each ADR represents two COH ordinary shares. On 26 April, APERIO reported a negative movement of 6 ADRs (equivalent to 3 shares), followed by positive movements of 222 ADRs (111 shares) on 27 April, 102 ADRs (51 shares) on 28 April, and 181 ADRs (91 shares) on 29 April.

Although these ADR volumes are small compared to broader BlackRock COH activity, their inclusion demonstrates that BlackRock’s aggregate relevant interest calculations for Australian substantial shareholder purposes encompass holdings and transactions across multiple jurisdictions and instruments, including ADR programs listed on US exchanges.

Roger Liddle Acts as Authorised Signatory for BlackRock

The notice lists Roger Liddle as the Authorised Signatory for BlackRock entities submitting the Form 604. This role is a standard compliance responsibility for substantial shareholder disclosures and does not imply personal trading or investment decisions by Mr. Liddle.

The filing date is recorded as 2 July 2026, which corresponds to the lodgement date. However, the transactions detailed in Annexure A cover activity starting from 26 April 2021. The lengthy period and voluminous filing are consistent with BlackRock’s practice of aggregating multiple transaction dates into comprehensive substantial shareholder disclosures.

Insights Into Institutional Interest in Cochlear from BlackRock’s Filing

Cochlear Limited is a major Australian healthcare and medical technology company, manufacturing cochlear implant systems and related hearing solutions sold worldwide. As a large-cap ASX-listed company with an international investor base, COH is commonly held in portfolios of global index and active fund managers, including BlackRock’s major index funds tracking indices like the MSCI World and S&P/ASX indices.

The volume and diversity of BlackRock entity activity in COH shares—spanning subsidiaries in Australia, the UK, the US, Japan, Singapore, Canada, and Hong Kong—underscore Cochlear’s status as a globally held ASX blue-chip. The filing suggests BlackRock’s aggregate holding in COH remained at a level maintaining substantial shareholder status throughout the period, although the exact total holding was not disclosed in the visible portion of Annexure A.

Interpreting Large Institutional Shareholding Changes in COH

Substantial shareholder notices from institutions like BlackRock are routine for ASX large-cap companies and do not alone indicate a directional investment stance. Many disclosed transactions—especially collateral transfers and in specie ETF creations and redemptions—are driven by index rebalancing, securities lending, and ETF portfolio management mechanics rather than fundamental views on Cochlear’s business prospects.

Nonetheless, investors may monitor trends in BlackRock’s aggregate COH holdings over time, as sustained increases or decreases could reflect broader shifts in fund flows into or out of healthcare or Australian equities. The immediate share price impact of this filing was not evident from public data. Investors will likely await Cochlear’s upcoming financial and operational updates for direct insights into company performance.

Future Disclosure Requirements and What to Expect from BlackRock

Australian law mandates that BlackRock file another Form 604 each time its aggregate relevant interest in Cochlear changes by 1% or more or when the nature of its interest alters. Given the frequent transactions across BlackRock’s many subsidiaries, additional substantial shareholder notices for COH are expected periodically as index rebalancing, ETF capital flows, and securities lending cause fluctuations in the group’s aggregate position.

Market participants tracking institutional ownership of Cochlear should note that the full 430-page Annexure A contains the complete transaction record for the disclosure period, though only a portion was summarized here. Investors seeking comprehensive details on BlackRock’s COH position changes are encouraged to review the full filing lodged with the ASX. The company did not disclose any updated total shareholding percentage in the publicly available section of the notice.